Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Demethoxy feruloyl acetone is a natural degradant of curcumin formed during heating, structurally similar to feruloylacetone but lacking a methoxy group on the aromatic ring[1][3]. It has demonstrated **antiproliferative and proapoptotic effects in colon cancer cell models**, specifically inhibiting proliferation and inducing cell cycle arrest (G2/M phase) and apoptosis, with mechanisms involving suppression of the phosphorylated mTOR/STAT3 pathway and activation of p53/p21 and cyclin-B1[1][3][5]. DFER also induces ROS elevation and mitochondrial changes in cancer cells. It has shown antioxidant activity, though markedly less than feruloylacetone[3]. Recently, DFER has been studied for its **potential to mitigate obesity-related glucose intolerance and muscle atrophy**, indicating possible metabolic benefits[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on demethoxy feruloyl acetone.